CompletedPhase 2NCT03861871
Fenfluramine in CDKL5 Deficiency Disorder (CDD)
Studying CDKL5-deficiency disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NYU Langone Health
- Principal Investigator
- Orrin Devinsky, MD, M.DNYU Langone Health
- Intervention
- Fenfluramine Hydrochloride(drug)
- Enrollment
- 7 enrolled
- Eligibility
- 2-18 years · All sexes
- Timeline
- 2019 – 2022
Study locations (1)
- New York Langone Health Comprehensive Epilespy Center, New York, New York, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03861871 on ClinicalTrials.govOther trials for CDKL5-deficiency disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06448663Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)University of Milan
- ACTIVE NOT RECRUITINGNCT05373719Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency DisorderLoulou Foundation
- ACTIVE NOT RECRUITINGPHASE3NCT05064878A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency DisorderZogenix, Inc.
- RECRUITINGNCT05558371International CDKL5 Clinical Research NetworkUniversity of Colorado, Denver